Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region

The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards

In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer

In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)